top of page

SUPERIOR SAFETY

Our Phase 1/2 human clinical study (N=36) showed numerically fewer and less severe side effects than currently marketed mRNA vaccines. You can see below a comparison of NeomiVac against other marketed mRNA Vaccines.

Side effect profile of the NeoVac (NeomiVac) in comparison with marketed mRNA Vaccines.

NeomiVac

BNT162b2

mRNA-1273

0%

20%

40%

60%

80%

100%

Mild

Moderate

Severe

bottom of page